Business development: A barometer of future success

Journal of Commercial Biotechnology

Volumn 10, Issue 2, 2003, Pages 123-130

  Valentine, Edmund L ^a  

^a MMC International   (United States)

Author keywords

Acquisition; Business development; Corporate culture; Leadership; Licensing

Indexed keywords

NEW DRUG;

ADMINISTRATIVE PERSONNEL; ARTICLE; BIOTECHNOLOGY; COMMERCIAL PHENOMENA; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; LEADERSHIP; LICENCE; ORGANIZATION AND MANAGEMENT; PATENT; PRODUCTIVITY;

EID: 3042733269     PISSN: 14628732     EISSN: None     Source Type: Journal    
DOI: 10.1057/palgrave.jcb.3040065     Document Type: Article

References (4)

1. Paragraph IV Certification refers to the paragraph under the Hatch-Waxman Amendments that allows a company to launch an equivalent product to the brand-name if the company's patents are proved invalid, via patent challenge, or if the patents are not infringed by the Amended New Drug Application (ANDA).
2. FDA (URL: http://www.fda.gov).
3. Biotechnology Industry Organization (2003), 'FDA Approves 20 New Biotech Products, 15 New Indications', 9th January (URL: http://www.bio.org).
4. URL: http://www.recap.com